Serendipitous Collaboration Leads to Potential Therapy for Liver Cancer

Colorized image of killer T cells

The old adage that says two heads are better than one certainly seems true for Mitchell Ho, Ph.D., a senior investigator in the Center for Cancer Research, and Xiaolin Wu, Ph.D., a principal scientist in the Genomics Technology Laboratory, a CCR Core at the Frederick National Laboratory. Together, these two scientists are using next-generation genomics technology to develop, in an animal model, a chimeric antigen receptor T-cell therapy that might help patients with hepatocellular carcinoma, the most common type of liver cancer.


Echoes from the Past: A New Institution for Cancer Research Is Born

Scientist viewing bottles on a rack

On October 18, 1971, President Richard Nixon emerged from the U.S. Army Post Headquarters at Fort Detrick into the sunlight of one of Frederick’s signature autumn mornings. Nearby, a crowd of dignitaries, Army officers, and journalists from local and national news outlets had gathered to hear his remarks about the former biowarfare research facility. He greeted them, paused to make a good-natured joke about the Baltimore Orioles, then delivered an announcement that altered the course of biomedical research in the United States.


NCI to Dedicate Millions of Dollars to Help Patients Enrolled in Clinical Trials

Photo of NCI Director Sharpless

During an address to the recent annual meeting of the American Society of Clinical Oncology, NCI Director Norman “Ned” Sharpless, M.D., announced that the National Cancer Institute is committing $10 million to support NCI-run clinical trials this year. The funds, which will be given in addition to the normal budget, are dedicated to trials conducted within the NCI Clinical Trials Network (NCTN) and the NCI Community Oncology Research Program.



Subscribe to Features